NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Cigna for its Veristrat test for guiding therapy in patients with non-small cell lung cancer.
The decision gives Biodesix more than 115 million covered lives for the test, which uses MALDI mass spec-based proteomic signatures to identify patients likely to respond to treatment with EGFR inhibitors. Cigna has 13.3 million US members.
The announcement follows several other recent positive coverage decisions for Veristrat. Last month UnitedHealthcare issued a positive coverage decision for the test, and in April CareFirst Blue Cross Blue Shield issued a positive coverage decision.